After the impact: the nutrients and flavonoids that actually earn their place in brain injury recovery
- Richard Moore
- Feb 2
- 16 min read
There is a moment after a brain injury when life splits into “before” and “after”. Not always dramatically, not always with a film-scene blackout. Sometimes it is subtler: a sentence that will not land, a light that feels too bright, a walk that suddenly requires concentration, a mood you do not recognise as your own.
Nutrition cannot undo the event. But the biology that follows the event is not passive. The injured brain becomes a high-demand construction site that is short on materials, flooded with inflammatory signals, and forced to keep the lights on while repairs happen. In that space, a small number of nutrients and phytonutrients have done something rare in this field: they have stepped out of theory and into human trials with outcomes that matter (Razmkon et al., 2011; Khazdouz et al., 2018; Tan et al., 2011; Zahedi et al., 2021; Khalili et al., 2022).
“Brain injury” is not one story, it is a whole genre
Clinically, “brain injury” is an umbrella term for damage that disrupts normal brain function, and it is usually grouped into traumatic brain injury (TBI), from an external force, and non-traumatic or acquired brain injury (ABI), from internal causes such as stroke, hypoxia, bleeding, infection, tumours, toxins, or metabolic failure. The reason this matters for nutrition is simple: the dominant biology changes depending on the injury mechanism and the phase of recovery, so the most defensible nutrition strategy is rarely one-size-fits-all. (Maas et al., 2022; Intiso et al., 2024)
In traumatic brain injury, that umbrella includes mild traumatic brain injury (mTBI), often called concussion, through to moderate and severe traumatic brain injury, contusions, diffuse axonal injury (DAI), penetrating injuries, blast injury, skull fracture with associated injury, and traumatic bleeding such as subdural haematoma, epidural haematoma, subarachnoid haemorrhage, and intracerebral haemorrhage. The common thread is external mechanical force, but the downstream problems can differ wildly, from microvascular dysfunction and neuroinflammation to swelling, impaired energy metabolism, and disrupted brain network connectivity (Maas et al., 2022).
In acquired brain injury, stroke splits into ischaemic stroke (blocked blood vessel) and haemorrhagic stroke (bleeding), while hypoxic-ischaemic injury follows loss of oxygen or reduced blood flow, for example after cardiac arrest or drowning. Infection and inflammation can injure brain tissue directly, and tumour and treatment effects can create damage through surgery, radiotherapy, swelling, or altered perfusion. Again, the dominant bottleneck differs: sometimes oxygen delivery is the story, sometimes inflammation and barrier dysfunction, sometimes rehabilitation capacity and neuroplasticity (Maas et al., 2022; Intiso et al., 2024).
And one final clarifier matters for readers, carers, and clinicians alike: neurodegenerative diseases such as Alzheimer’s and Parkinson’s involve brain damage, but they are usually described as neurodegeneration, not “brain injury”, because the time-course and primary drivers are different. That distinction is one reason evidence from dementia prevention cannot be pasted directly onto concussion rehabilitation, even when a compound is biologically interesting (Maas et al., 2022; Tang et al., 2016).
The second injury: the biochemical aftershocks that decide the trajectory
The initial hit, bleed, blockage, or oxygen drop is the first chapter. What follows can be the longer book.
After brain injury, the brain can enter a period of secondary injury biology, where oxidative stress, inflammatory signalling, excitotoxicity, mitochondrial dysfunction, blood-brain barrier disruption, and microvascular impairment amplify damage and slow recovery. This is one reason timing and context matter so much: a nutrient that is helpful in the intensive care unit may be irrelevant months later, while a nutrient that supports neuroplasticity in rehabilitation may not move the needle in the first 72 hours (Razmkon et al., 2011; Zahedi et al., 2021; Tan et al., 2011; Intiso et al., 2024).
If you want a single image, think of the brain as a city whose transport system, power generation, and waste removal are all being repaired at the same time, while the city still has to function. Some interventions try to reduce the fire risk early. Some try to stabilise supply lines. Some try to increase the quality of rebuilding.
With that frame, we can stop chasing everything that sounds plausible and focus on what has actually shown signal in humans.
The ICU signals that make clinicians lean forward
Vitamin C and Vitamin E: when antioxidant theory finally shows up as outcomes
Oxidative stress appears repeatedly in brain injury biology, but antioxidant theory alone is not enough. What changes the conversation is human data in severe traumatic brain injury.
A randomised, double-blind controlled trial in severe head injury tested vitamin C (ascorbic acid) and vitamin E (alpha-tocopherol) and reported improvements in outcomes including mortality and aspects of clinical course. That does not make the strategy universally effective, but it moves it into the category of “supported by controlled human data in severe TBI” (Razmkon et al., 2011).
More recently, a propensity score matched analysis in severe traumatic brain injury reported associations between use of vitamins C and E and improved outcomes including Glasgow Outcome Scale Extended (GOS-E) and reduced intensive care unit (ICU) length of stay. Propensity matching is not randomisation, but it is an attempt to reduce baseline imbalance, and it strengthens the signal when viewed alongside earlier trial data (Khalili et al., 2022).
What this means in practice is not “megadose antioxidants for everyone”. It means that in severe, high-inflammatory, high-oxidative-load contexts, antioxidant vitamin strategies have enough human outcome data to be a serious discussion in medically supervised care pathways (Razmkon et al., 2011; Khalili et al., 2022).
Zinc: one of the cleaner human trial stories in severe head trauma
Zinc is woven into immune function, wound repair, and neural signalling. After severe trauma, zinc status can drop, and that creates a predictable problem: you are trying to rebuild while short on key hardware.
A double-blind randomised clinical trial in severe head trauma reported that zinc supplementation improved clinical outcomes including Glasgow Outcome Scale (GOS) and Sequential Organ Failure Assessment (SOFA) scores, alongside improved inflammatory markers and shorter length of stay. The mortality difference was borderline, but the direction of effect and clinically relevant endpoints are why zinc keeps returning in evidence-informed brain injury nutrition conversations (Khazdouz et al., 2018).
This is not a license for indiscriminate dosing. It is a reminder that correcting likely deficits in critical illness can be more powerful than adding exotic compounds to an already overwhelmed system (Khazdouz et al., 2018).
Probiotics: not “wellness”, but infection risk and immune drift
After severe traumatic brain injury, gut barrier function, immune signalling, and microbiota composition can shift. In ICU settings, infection is not a footnote, it can be a turning point.
A prospective randomised pilot study in severe traumatic brain injury reported that prophylactic probiotics attenuated a deviated T helper 1 to T helper 2 immune response and reduced nosocomial infection rate, particularly later in the course. That matters because preventing infection is one of the simplest ways to avoid avoidable setbacks. (Tan et al., 2011).
When the evidence is pooled, the story becomes more cautious. A recent systematic review and meta-analysis evaluated probiotics in traumatic brain injury and concluded that evidence remains limited and heterogeneous, with a need for stronger trials. This is exactly why brain injury nutrition needs both optimism and restraint: individual trials can look impressive, but the signal has to survive aggregation and replication (Asaadi et al., 2024).
A practical interpretation is narrow but useful: in some ICU contexts, selected probiotic strategies may help reduce infections, but the current evidence base does not justify promising universal neurological recovery benefits (Tan et al., 2011; Asaadi et al., 2024).
Curcuminoids: a twist you only see by reading the trial properly
Curcuminoids are biologically interesting polyphenols, often discussed as anti-inflammatory agents. In critically ill traumatic brain injury patients, a randomised double-blind placebo-controlled trial tested 500 mg curcuminoids daily for 7 days via enteral nutrition.
Here is the nuance that matters: the trial reported no overall group effects across all dependent variables, but within-group changes showed significant reductions in inflammatory markers such as interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and C-reactive protein (CRP) in the curcuminoids group, and improvements in Acute Physiology and Chronic Health Evaluation II (APACHE II) and Modified Nutrition Risk in the Critically ill (NUTRIC) scores compared with placebo. The authors concluded short-term curcuminoids may benefit inflammation, clinical outcomes, and nutritional status in this ICU TBI context(Zahedi et al., 2021).
This is a classic example of why “did it work?” is not a single question. The trial suggests potential benefit in inflammatory and severity metrics, but it does not justify overselling broad recovery outcomes. Still, it earns a place on the shortlist because it is not just mechanistic speculation, it is a controlled human ICU trial with clinically meaningful measures (Zahedi et al., 2021).
French maritime pine bark extract: when a flavonoid-rich extract steps into mortality territory
French maritime pine bark extract, sometimes standardised as Oligopin, is rich in polyphenols such as procyanidins. In an ICU randomised controlled trial in traumatic brain injury, supplementation was reported to reduce inflammation and improve clinical and nutritional status, with a reported reduction in mortality. That is a dramatic endpoint for a nutritional intervention, and it is exactly the kind of result that should trigger both interest and the question, “Will this replicate?” (Malekahmadi et al., 2021).
In brain injury nutrition, this sits in the “promising, high-stakes signal, needs replication” category. It is not a casual supplement story. It is an ICU intervention signal (Malekahmadi et al., 2021).
Concussion and mild TBI: the quieter injuries with loud biology
Mild traumatic brain injury can be “mild” on scans and anything but mild in lived experience. Cerebrovascular control, cortical oxygenation responses, autonomic regulation, sleep architecture, and neuroinflammatory signalling can all be disturbed after concussion, which is why the most useful nutrition conversations often focus on systems, not slogans (Gratton et al., 2020; Barlow et al., 2021).
Cocoa flavanols: blood flow biology with a concussion-shaped silhouette
A 2020 randomised controlled study in healthy adults reported that cocoa flavanols improved measures of cerebrovascular reactivity and cortical oxygenation responses. This matters because concussion and other brain injuries can involve disturbed vascular reactivity and neurovascular coupling, and anything that supports vascular responsiveness becomes mechanistically relevant even before we have definitive concussion rehab trials for that compound (Gratton et al., 2020).
A systematic review and meta-analysis of clinical trials concluded cocoa or chocolate interventions can influence cognitive outcomes, while also highlighting heterogeneity and population differences that limit how cleanly those effects can be mapped onto injured brains. That is a useful reality check: cocoa flavanols show measurable human cognitive and vascular effects, but the leap from “healthy adult cognition” to “post-concussion recovery” is a leap, not a step. (Shateri et al., 2023)
There is also a prevention and recurrence angle for acquired brain injury. Meta-analyses of prospective cohorts suggest higher dietary flavonoid intake is associated with lower stroke risk. That does not replace acute rehabilitation, but it does matter for long-term risk reduction in stroke-prone populations (Tang et al., 2016).
N-acetylcysteine: from blast injury to post-concussion syndrome
N-acetylcysteine (NAC) is best known as a glutathione precursor and as a therapy in paracetamol overdose. In brain injury, the interest is redox signalling and oxidative stress modulation.
In blast-induced mild traumatic brain injury, a double-blind placebo-controlled study tested NAC and reported improved symptom resolution, with timing appearing important. This is one reason NAC has remained on serious shortlists rather than fading as a trend (Hoffer et al., 2013).
More recently, a 2025 study in post-concussion syndrome evaluated NAC in an outpatient setting, framing benefit around changes in resting-state functional connectivity and cognitive-affective symptoms. This is a different injury window and a different endpoint style, but it reinforces the point that NAC continues to attract human research attention beyond acute blast contexts. (Monti et al., 2025)
A 2024 study also assessed NAC effects on brain function and chronic symptoms in mild traumatic brain injury using neuroimaging and symptom outcomes, again pointing toward ongoing investigation of NAC in chronic mTBI contexts. (Vedaei et al., 2024)
NAC is not “the answer”. But it is one of the few compounds that keeps resurfacing because it has multiple human study threads rather than a single isolated headline (Hoffer et al., 2013; Vedaei et al., 2024; Monti et al., 2025)
Branched-chain amino acids: the unexpected pilot trial with symptom signal
Branched-chain amino acids (BCAA) are usually discussed in muscle and exercise circles, but the brain also uses these amino acids, and concussion can perturb metabolic and neurotransmitter-linked pathways.
A 2024 pilot, double-blind randomised controlled trial in concussed adolescents and young adults reported a dose-response effect in reducing concussion symptoms and a return to baseline physical activity in those treated with higher total BCAA doses. The authors were explicit about limitations such as small sample size and missing data, but even with that caveat, this stands out because it is controlled human concussion data with functional outcomes (Corwin et al., 2024).
Magnesium and riboflavin: the migraine-adjacent twist that keeps showing up in concussion clinics
Concussion headaches and migraine biology can overlap in some individuals, which is one reason nutrients associated with migraine prevention keep appearing in concussion research and practice.
A randomised cohort study in acute concussion reported that oral magnesium supplementation improved symptoms compared with control in an emergency department-related setting. This does not declare magnesium a universal concussion therapy, but it adds controlled human data to a mechanistically plausible nutrient (Standiford et al., 2021).
Riboflavin, also known as vitamin B2, has been studied in sport-related concussion contexts, aligning with its roles in mitochondrial energy metabolism. Evidence remains emerging, but the direction of research reflects a recurring theme: concussion management often intersects with the biology of energy production and neurovascular stability. (Siahaan et al., 2025)
Sleep is not a side quest: melatonin has trial-level relevance in post-concussion symptoms
Sleep disruption after brain injury can amplify pain, mood symptoms, and cognitive dysfunction, which is why sleep is often the lever that changes everything else downstream.
A randomised clinical trial evaluated melatonin for sleep disturbance in youth with persistent post-concussion symptoms following mild traumatic brain injury, placing melatonin in the category of “studied, not assumed”. This matters because improving sleep is not simply comfort, it can be a biological amplifier of recovery capacity (Barlow et al., 2021).
Omega-3 fatty acids: a story of promise, mixed results, and growing precision
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are structural and signalling lipids in the brain, and they are repeatedly proposed as neuroprotective. The hard truth is that the human evidence is not uniformly positive, and that is exactly why the omega-3 story is worth telling.
In adolescent sport-related concussion, a pilot randomised controlled trial of DHA did not demonstrate a clear benefit on the primary clinical recovery outcomes, reminding us that “biological plausibility” does not guarantee functional improvement in real-world concussion trajectories (Miller et al., 2022).
At the same time, omega-3 research is increasingly focusing on biomarkers, exposure, and prevention models in contact sports. A 2024 systematic review and meta-analysis in American football contexts evaluated omega-3 supplementation and its associations with neurofilament light chain and other measures, reflecting the field’s shift toward measuring axonal stress and sub-concussive exposure rather than relying only on symptom scales. (Heileson et al., 2024)
And in 2025, a randomised placebo-controlled trial protocol was published to investigate DHA and EPA in repetitive sub-concussive injury, signalling that the next phase of omega-3 research may be more targeted, more mechanistically measured, and better powered. (Beauregard et al., 2025).
For people living with brain injury, the practical takeaway is not “take fish oil and you are covered”. It is that omega-3s remain a biologically important foundation, but clinical outcome benefits likely depend on dose, timing, injury context, and endpoints, and the best claims are currently narrower than many marketing narratives (Miller et al., 2022; Heileson et al., 2024; Beauregard et al., 2025).
Creatine: the paediatric pilot data that refuses to be ignored
Creatine is central to cellular energy buffering, which makes it conceptually relevant when brain energy metabolism is strained.
In paediatric traumatic brain injury, preliminary human work has reported improvements in several parameters including post-traumatic symptoms such as headache, dizziness, and fatigue, and reduced intensive care-related measures in pilot settings. These studies are not definitive, and adult randomised trials remain limited, but creatine remains notable because it is anchored to human data rather than purely animal models (Sakellaris et al., 2006; Sakellaris et al., 2008).
Vitamin D: acquired brain injury rehab is where it becomes clinically interesting
Vitamin D shows up repeatedly in neurological observational literature, but what matters most here is intervention evidence.
A 2024 pilot controlled randomised study evaluated vitamin D supplementation during rehabilitation in severe acquired brain injury and reported a better clinical course and functional outcome in that rehabilitation context. This positions vitamin D less as an abstract “immune vitamin” and more as a potentially relevant part of rehabilitation physiology in populations that often present with low vitamin D status and high disability burden. (Intiso et al., 2024).
The “did not deliver what we hoped” shelf, because this matters too
Some interventions become famous because they sound like they should work, then the best trials quietly disagree.
Citicoline is a classic example. It has strong mechanistic appeal, but in the large Citicoline Brain Injury Treatment Trial (COBRIT), citicoline did not improve functional and cognitive status after traumatic brain injury. This is why brain injury nutrition should be anchored in outcomes, not narratives (Zafonte et al., 2012).
Omega-3 treatment in concussion, as above, has also produced mixed clinical results, which is not failure so much as a signal that the right question may not be “does it work?” but “for whom, when, at what dose, and measured how?” (Miller et al., 2022; Beauregard et al., 2025).
Curcuminoids provide another useful nuance. Even when inflammatory markers improve, overall group effects and hard outcomes may not move in parallel, especially in short ICU trials where multiple competing interventions are running simultaneously (Zahedi et al., 2021).
So what should someone actually eat, when the goal is recovery biology rather than food rules?
The strongest food pattern across the evidence is not exotic. It is a pattern that reliably supplies the substrates the brain keeps spending during repair: high-quality protein, omega-3 rich seafood or equivalent sources, deeply coloured plants that deliver flavonoids and polyphenols, fibre that feeds microbial metabolites, and micronutrient density that supports immune regulation and energy metabolism. The difference, after brain injury, is that these are not lifestyle accessories. They are raw materials (Gratton et al., 2020; Tang et al., 2016; Tan et al., 2011; Intiso et al., 2024).
If you want to map foods to the most defensible compound categories in this blog, it looks like this: cocoa flavanols from minimally processed cocoa, berries and citrus for broader flavonoid coverage, oily fish for DHA and EPA, zinc-rich foods such as seafood and meat or carefully chosen alternatives, fermented foods and fibre-rich plants for gut resilience, and protein distributed across the day to support rehabilitation demands and amino-acid availability. That pattern does not claim to be a cure. It claims to be aligned with the best-supported repair biology (Gratton et al., 2020; Tang et al., 2016; Khazdouz et al., 2018; Tan et al., 2011; Heileson et al., 2024).
The shortlist, if you only remember one section
In severe traumatic brain injury and ICU contexts, the nutrients with some of the clearest human outcome signals include vitamins C and E, zinc, and selected ICU probiotic strategies, with additional promising trial signals for French maritime pine bark extract and curcuminoids, though replication and context remain important (Razmkon et al., 2011; Khalili et al., 2022; Khazdouz et al., 2018; Tan et al., 2011; Malekahmadi et al., 2021; Zahedi et al., 2021).
In concussion and mild traumatic brain injury, the human data threads that stand out include NAC, BCAA, magnesium, and sleep-targeted melatonin in persistent post-concussion symptoms, while cocoa flavanols remain mechanistically compelling for vascular reactivity but are not yet a proven concussion rehabilitation therapy (Hoffer et al., 2013; Corwin et al., 2024; Standiford et al., 2021; Barlow et al., 2021; Gratton et al., 2020; Monti et al., 2025).
In acquired brain injury and rehabilitation contexts, vitamin D supplementation has emerging randomised evidence in severe acquired brain injury rehabilitation, while higher dietary flavonoid intake is associated with lower stroke risk in cohort meta-analysis data, which is relevant to prevention and recurrence risk conversations (Intiso et al., 2024; Tang et al., 2016).
Build a recovery plan that fits the injury, the person, and the evidence
At You Nutrition Clinic, Becki supports people living with brain injury and the carers who walk beside them. Her integrative, functional approach is grounded in systems biology and biochemical individuality, addressing cognition, neuroplasticity, pain, energy metabolism, inflammatory pathways, and the gut-brain axis. She integrates evidence-informed nutritional therapy with movement science to support neurological recovery, functional capacity, and long-term health.
If you want a plan that turns complex research into a clear, personalised strategy you can actually follow, contact Becki at You Nutrition Clinic.
Book a free initial call: admin@younutritionclinic.com
🧩 Connect with us
For research updates, practical tips, and ongoing inspiration, follow us on Instagram:
Stay curious. Stay hopeful. Support your brain. 🧠
References
Asaadi, H., et al. (2024). Probiotic-based therapy as a new useful strategy for the treatment of patients with traumatic brain injury: A systematic review and meta-analysis. BMC Infectious Diseases, 24(1), 1240. https://doi.org/10.1186/s12879-024-10146-0
Barlow, K. M., et al. (2021). Efficacy of melatonin for sleep disturbance in children with persistent post-concussion symptoms following mild traumatic brain injury: A randomized clinical trial. Journal of Neurotrauma. https://doi.org/10.1089/neu.2020.7154
Beauregard, L. H., et al. (2025). Investigating omega-3 fatty acids’ neuroprotective effects in repetitive subconcussive neural injury: Study protocol for a randomized placebo-controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0321808
Corwin, D. J., et al. (2024). A pilot randomized controlled trial of the tolerability, safety, and efficacy of branched-chain amino acids in concussed adolescents and young adults. Journal of Neurotrauma.
Gratton, G., et al. (2020). Dietary flavanols improve cerebral cortical oxygenation and cognition in healthy adults. Scientific Reports, 10, 19409. https://doi.org/10.1038/s41598-020-76160-9
Hoffer, M. E. (2013). Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetylcysteine (randomized, placebo-controlled study).
Heileson, J. L., et al. (2024). Omega-3 fatty acid supplementation in American football athletes: A systematic review and meta-analysis (biomarker-focused evidence synthesis).
Intiso, D., Centra, A. M., Gravina, M., et al. (2024). Vitamin D supplementation in functional recovery of subjects with severe acquired brain injury: A pilot controlled randomized study. Neurotrauma Reports, 5(1), 606–616. https://doi.org/10.1089/neur.2023.0128
Khalili, H., et al. (2022). The effect of vitamins C and E on clinical outcomes of patients with severe traumatic brain injury: A propensity score matching study. Surgical Neurology International, 13, 548.
Khazdouz, M., et al. (2018). Impact of zinc supplementation on the clinical outcomes of patients with severe head trauma: A double-blind randomized clinical trial.
Maas, A. I. R., et al. (2022). Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research (consensus overview).
Malekahmadi, M., et al. (2021). The effect of French maritime pine bark extract supplementation on inflammation, nutritional and clinical status in critically ill patients with traumatic brain injury: A randomized controlled trial.
Miller, Z. M., et al. (2022). A pilot randomized controlled trial of docosahexaenoic acid (DHA) for sport-related concussion in adolescents. Clinical Pediatrics.
Monti, D. A., et al. (2025). Changes in resting-state functional connectivity and cognitive-affective symptoms in patients with post-concussion syndrome treated with N-acetylcysteine. Journal of Head Trauma Rehabilitation, 40(3), E196–E207.
Razmkon, A., et al. (2011). Administration of vitamin C and vitamin E in severe head injury: A randomized double-blind controlled trial. Clinical Neurosurgery, 58, 133–137. https://doi.org/10.1227/neu.0b013e3182279a8f
Sakellaris, G., et al. (2006). Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration (pilot human study).
Sakellaris, G., et al. (2008). Prevention of traumatic headache, dizziness and fatigue with creatine administration: A pilot study. Acta Paediatrica.
Shateri, Z., et al. (2023). Effects of chocolate on cognitive function in healthy adults: A systematic review and meta-analysis on clinical trials. Phytotherapy Research.
Standiford, L., et al. (2021). Oral magnesium supplementation in acute concussion: A randomized cohort study.
Tan, M., et al. (2011). Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain injury: A prospective randomized pilot study. Critical Care.
Tang, Z., Li, M., et al. (2016). Dietary flavonoid intake and the risk of stroke: A dose-response meta-analysis of prospective cohort studies. BMJ Open, 6, e008680.
Vedaei, F., et al. (2024). Treatment effects of N-acetylcysteine on resting-state functional MRI and cognitive performance in patients with chronic mild traumatic brain injury. Frontiers in Neurology.
Zahedi, H., et al. (2021). Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: A randomized double-blind placebo-controlled trial. Phytotherapy Research, 35(8), 4605–4615.
Zafonte, R. D., et al. (2012). Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: The COBRIT randomized clinical trial. JAMA.
Comments